Derek C Angus,Alison J Huang,Roger J Lewis,Amy P Abernethy,Robert M Califf,Martin Landray,Nancy Kass,Kirsten Bibbins-Domingo,JAMA Summit on Clinical Trials Participants,Ali B Abbasi,Kaleab Z Abebe,Stacey J Adam,Jamy Ard,Rachel A Bender Ignacio,Scott M Berry,Deepak L Bhatt,Robert O Bonow,Marc Bonten,Sharon A Brangman,John Brownstein,Melinda J B Buntin,Atul J Butte,Marion K Campbell,Anne R Cappola,Anne C Chiang,Deborah Cook,Steven R Cummings,Gregory Curfman,Laura J Esserman,Lee A Fleisher,Joseph B Franklin,Ralph Gonzalez,Cynthia I Grossman,Tufia C Haddad,Roy S Herbst,Adrian F Hernandez,Diane P Holder,Leora Horn,Grant D Huang,Alison Huang,Rohan Khera,Walter J Koroshetz,Harlan M Krumholz,Tracy A Lieu,Preeti N Malani,Christa Lese Martin,Mark McClellan,Mary M McDermott,Stephanie R Morain,Susan A Murphy,Stuart G Nicholls,Stephen J Nicholls,Peter J O'Dwyer,Bhakti K Patel,Eric Peterson,Sheila A Prindiville,Joseph S Ross,Kathryn M Rowan,Gordon Rubenfeld,Christopher W Seymour,Rod S Taylor,Joanne Waldstreicher,Tracy Y Wang

Abstract:Importance: Optimal health care delivery, both now and in the future, requires a continuous loop of knowledge generation, dissemination, and uptake on how best to provide care, not just determining what interventions work but also how best to ensure they are provided to those who need them. The randomized clinical trial (RCT) is the most rigorous instrument to determine what works in health care. However, major issues with both the clinical trials enterprise and the lack of integration of clinical trials with health care delivery compromise medicine's ability to best serve society. Observations: In most resource-rich countries, the clinical trials and health care delivery enterprises function as separate entities, with siloed goals, infrastructure, and incentives. Consequently, RCTs are often poorly relevant and responsive to the needs of patients and those responsible for care delivery. At the same time, health care delivery systems are often disengaged from clinical trials and fail to rapidly incorporate knowledge generated from RCTs into practice. Though longstanding, these issues are more pressing given the lessons learned from the COVID-19 pandemic, heightened awareness of the disproportionate impact of poor access to optimal care on vulnerable populations, and the unprecedented opportunity for improvement offered by the digital revolution in health care. Four major areas must be improved. First, especially in the US, greater clarity is required to ensure appropriate regulation and oversight of implementation science, quality improvement, embedded clinical trials, and learning health systems. Second, greater adoption is required of study designs that improve statistical and logistical efficiency and lower the burden on participants and clinicians, allowing trials to be smarter, safer, and faster. Third, RCTs could be considerably more responsive and efficient if they were better integrated with electronic health records. However, this advance first requires greater adoption of standards and processes designed to ensure health data are adequately reliable and accurate and capable of being transferred responsibly and efficiently across platforms and organizations. Fourth, tackling the problems described above requires alignment of stakeholders in the clinical trials and health care delivery enterprises through financial and nonfinancial incentives, which could be enabled by new legislation. Solutions exist for each of these problems, and there are examples of success for each, but there is a failure to implement at adequate scale. Conclusions and relevance: The gulf between current care and that which could be delivered has arguably never been wider. A key contributor is that the 2 limbs of knowledge generation and implementation-the clinical trials and health care delivery enterprises-operate as a house divided. Better integration of these 2 worlds is key to accelerated improvement in health care delivery.

A crisis in clinical research

The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective

Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation

Impact of COVID-19 on Clinical Research Units (CRUs)

Defining the critical hurdles in cancer immunotherapy

Improving Access to Patient-Focused, Decentralized Clinical Trials Requires Streamlined Regulatory Requirements: An ASCO Research Statement

Ethical rationale for better coordination of clinical research on COVID-19

Ethical Challenges in Clinical Research During the COVID-19 Pandemic

Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

How the clinical research community responded to the COVID-19 pandemic: An analysis of the COVID-19 clinical studies in ClinicalTrials.gov

Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial

The ethics of clinical research in the era of COVID-19

Innovation and strategy in clinical research with the SCIOSM method

The Integration of Clinical Trials With the Practice of Medicine: Repairing a House Divided

The COVID Pandemic and Surgical Innovation in the United States

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision

Roundtable discussion. Investigational exclusion, clinical trials, and cancer

Optimizing Clinical Research Procedures in Public Health Emergencies

Precision medicine: affording the successes of science

Fundamental Shifts in Research, Ethics and Peer Review in the Era of the COVID-19 Pandemic

Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post-COVID-19 Global Context: A Modified Delphi Consensus Process